The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 08, 2015
Filed:
Aug. 31, 2011
Satoshi Obika, Osaka, JP;
Takeshi Imanishi, Osaka, JP;
Tsuyoshi Yamamoto, Osaka, JP;
Keisuke Narukawa, Osaka, JP;
Mariko Shiba, Osaka, JP;
Tetsuji Yamaoka, Osaka, JP;
Hidetaka Torigoe, Tokyo, JP;
Atsushi Yamashita, Osaka, JP;
Yoichi Tachibana, Osaka, JP;
Sachiro Kakinoki, Osaka, JP;
Kiyomi Sasaki, Tokyo, JP;
Satoshi Obika, Osaka, JP;
Takeshi Imanishi, Osaka, JP;
Tsuyoshi Yamamoto, Osaka, JP;
Keisuke Narukawa, Osaka, JP;
Mariko Shiba, Osaka, JP;
Tetsuji Yamaoka, Osaka, JP;
Hidetaka Torigoe, Tokyo, JP;
Atsushi Yamashita, Osaka, JP;
Yoichi Tachibana, Osaka, JP;
Sachiro Kakinoki, Osaka, JP;
Kiyomi Sasaki, Tokyo, JP;
Osaka University, Osaka, JP;
National Cerebral and Cardiovascular Center, Osaka, JP;
Tokyo University of Science Education Foundation Administrative Organization, Tokyo, JP;
Abstract
An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4'-position and 2′-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.